Recent approaches for sodium-glucose Co-transporter 2 inhibitors in the management of non-alcoholic fatty liver disease

NAFLD is an umbrella term for a variety of illnesses of ranging severity starts with simple steatosis, develops to non-alcoholic steatohepatitis (NASH), then cirrhosis, and if not controlled, eventually can develop to fibrosis and even hepatocellular carcinoma (HCC). The disease is linked to obesity, insulin resistance, and type 2 diabetes mellitus (T2DM), thus addressing these interconnected disorders could be an effective approach for its management. This review gives an overview the most recent relevant research studies and the on-going therapeutic options for NAFLD focusing on the recently discovered sodium glucose cotransporter 2 inhibitors (SGLT2i), the new antihyperglycemic class of drugs which recently gained adequate popularity, as well as their efficacy and applications in experimental and clinical work.